MedTrace Logo

Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer

NCT03646409 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 542

Last updated 2020-01-13

No results posted yet for this study

Summary

This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. Additionally, the predictive value of the Khorana score and several other VTE and bleeding prediction scores and risk factors will be evaluated.

Conditions

  • Venous Thromboembolism
  • Esophagus Cancer
  • Bleeding
  • Chemotherapy Effect

Interventions

OTHER

Venous thromboembolic event, arterial thromboembolic event, bleeding events

Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Harry R Büller, Prof. dr. · Vascular Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-11
Primary Completion
2018-10-01
Completion
2018-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03646409 on ClinicalTrials.gov